Janus Henderson Group PLC Arcellx, Inc. Transaction History

Janus Henderson Group PLC

$188 Billion
Q4 2024

A detailed history of Janus Henderson Group PLC transactions in Arcellx, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 1,557,092 shares of ACLX stock, worth $97.6 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

1,557,092

Previous 2,011,950 22.61%

Holding current value

$97.6 Million

Previous $168 Million 29.42%

% of portfolio

0.06%

Previous 0.09%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$75.39 - $106.53 $34.3 Million - $48.5 Million	-454,858 Reduced 22.61%	1,557,092 $119 Million
Q3 2024 Nov 14, 2024	BUY	$50.91 - $86.61 $5.57 Million - $9.47 Million	109,332 Added 5.75%	2,011,950 $168 Million
Q2 2024 Aug 14, 2024	BUY	$49.74 - $66.98 $18.9 Million - $25.5 Million	380,309 Added 24.98%	1,902,618 $105 Million
Q1 2024 May 15, 2024	SELL	$51.85 - $73.49 $824,466 - $1.17 Million	-15,901 Reduced 1.03%	1,522,309 $106 Million
Q4 2023 Feb 14, 2024	SELL	$31.75 - $57.99 $7.53 Million - $13.8 Million	-237,228 Reduced 13.36%	1,538,210 $85.4 Million
Q3 2023 Nov 14, 2023	BUY	$31.51 - $37.4 $667,728 - $792,543	21,191 Added 1.21%	1,775,438 $63.7 Million
Q2 2023 Aug 14, 2023	BUY	$27.49 - $46.9 $4.59 Million - $7.83 Million	166,995 Added 10.52%	1,754,247 $55.5 Million
Q1 2023 May 15, 2023	SELL	$26.92 - $33.94 $2.29 Million - $2.88 Million	-84,895 Reduced 5.08%	1,587,252 $48.9 Million
Q4 2022 Feb 14, 2023	BUY	$17.18 - $33.0 $8.76 Million - $16.8 Million	510,038 Added 43.89%	1,672,147 $51.8 Million
Q3 2022 Nov 14, 2022	SELL	$16.67 - $22.04 $1.55 Million - $2.04 Million	-92,700 Reduced 7.39%	1,162,109 $21.8 Million
Q2 2022 Aug 15, 2022	BUY	$7.21 - $24.43 $9.05 Million - $30.7 Million	1,254,809 New	1,254,809 $22.7 Million

Others Institutions Holding ACLX

# of Institutions

224

Shares Held

45.1M

Call Options Held

434K

Put Options Held

433K

View Full List

About Arcellx, Inc.

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $2.75B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

More about ACLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC Arcellx, Inc. Transaction History